Meaningful Use Reporting for Physicians
Kentucky Cancer Registry (KCR) is ready to receive cancer data electronically from all interested providers who diagnose or treat cancer patients.
To enhance cancer surveillance in Kentucky and to support the Meaningful Use Stage 2 option of physician cancer reporting from a certified electronic health record (EHR) system, KCR is currently accepting data electronically from physician providers.
Our efforts are coordinated with the Kentucky Health Information Exchange (KHIE) and the Kentucky Regional Extension Center (KY-REC) who offer additional services in support of meaningful use objectives.
If you are interested in electronic reporting, please contact:
David Rust
Email: dave.rust@uky.edu
Additional information:
KY-REC
Toll Free: 1-888-KY-REC-EHR
Phone: 859-323-3090
Web: http://kentuckyrec.com/
KHIE
Web: http://khie.ky.gov/PAGES/INDEX.ASPX
MU Stage 2 Menu Measure 5: Reporting Cancer (PDF)
Kentucky Cancer Registry Reporting Guidelines for Meaningful Use
The full text below can be downloaded here in PDF format.
January 6, 2016
The Kentucky Cancer Registry was established in 1990 by the Kentucky State Legislature to conduct ongoing population-based surveillance of cancer in the Commonwealth (Please see Appendix KRS 214.556). All cases of primary malignant disease diagnosed or treated at a Kentucky health care facility on or after January 1, 1991, should be reported to the Kentucky Cancer Registry (KCR). This document provides basic guidelines for reporting to the KCR for the purposes of Meaningful Use.
ELIGIBLE PROVIDERS
Eligible providers for specialized reporting to a central cancer registry include those providers directly involved in the diagnosis and/or treatment of the primary malignant disease. In order to be eligible to report to KCR for Meaningful Use (MU), the provider must first comply with MU rules and regulations and must utilize an Electronic Health Record (EHR) system that is certified for cancer registry reporting.
KCR's priority interests are in providers that specialize in cancer such as private hematology oncology groups, freestanding radiation therapy centers, nonhospital dermatologists, nonhospital urologists, and freestanding diagnostic radiology offices. However, KCR will accept reports from other providers who can provide meaningful cancer data that, at a minimum, must include:
- Patient demographics: Name, Address, Age, Race, Sex, Date of Birth, and SSN
- Confirmed cancer diagnosis: Cancer site, histologic type, behavior, laterality, and diagnosis date
- Treatment and referral information
CASES TO BE REPORTED
Reportable cases are usually described by the terms: carcinoma, sarcoma, melanoma, leukemia, or lymphoma. Reportable cases may be identified by specified ICD-10-CM codes. Please refer to the case finding list of these codes here. They may also be classified by ICD-O topography, morphology, and behavior codes. Effective with diagnoses in 2010, all hematopoietic and lymphoid neoplasms classified with a behavior code 3 in the "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" are reportable. These fall into the histology code range of 9590/3 - 9992/3. Only in-situ and malignant neoplasms are reportable (behavior codes 2 and 3); benign, borderline, and metastatic tumors are not reportable to the KCR, except as noted below. However, if a term is used which usually has a behavior code of '0' or '1', but is verified by a pathologist as in-situ or malignant (behavior code 2 or 3), these cases are reportable.
THE ONLY EXCEPTIONS to this are:
- Neoplasms of the skin (ICD-O Topography codes C44.0 to C44.9) with the following ICD-O Morphology codes are NOT reportable:
- M 8000-8005 Neoplasms, NOS
- M 8010-8046 Epithelial neoplasms
- M 8050-8084 Squamous cell neoplasms of the skin
- M 8090-8110 Basal cell neoplasms of the skin NOTE: Localized basal and squamous cell skin cancers greater than 5 cm at diagnosis, as well as those diagnosed at a regional or distant stage, were previously required by ACoS for approved hospitals prior to 2003. They are not required to be reported to KCR or to ACoS after January 1, 2003.
- Cases of intraepithelial neoplasia, Grade III, of the cervix or prostate (M-8077/2). These are often designated by terms such as CIN III or PIN III. These cases are not required to be abstracted or reported.
- Any carcinoma in-situ of the cervix is not to be reported to KCR, as of January 1, 1998. This includes any type of malignancy with a topography code of C53 and a behavior code of 2.
- Pilocytic astrocytoma (C71.__, M-9421/1) is required to be reported as a malignant brain tumor with 9421/3.
- As of January 1, 2004, the following non-malignant primary intracranial and central nervous system tumors with a behavior code of /0 or /1 (benign and borderline, or "non-malignant") are required to be reported, regardless of histologic type, for these ICD-O-3 topography codes.
Topography codes for these benign brain tumors are available on the KCR website here.
PATIENTS TO BE REPORTED
All patients first seen and/or treated at each Kentucky facility after January 1, 1991 for a diagnosis of cancer should be reported to the Kentucky Cancer Registry. This includes inpatient admissions and patients seen in ambulatory care settings that are hospital affiliated. It includes all clinical diagnoses of cancer, whether histologically confirmed or not. It also includes patients diagnosed as autopsy.
As of January 1, 1995, all patients seen or treated in any licensed health facility in the state, which provides diagnostic or treatment services to cancer patients, shall report cases to the Kentucky Cancer Registry. Physicians in private practice should report any cases of cancer diagnosed or treated in their offices which are not otherwise reported to KCR by another health care facility.
PATIENTS NOT REQUIRED TO BE REPORTED
- Patients who are seen only in consultation to confirm a cancer diagnosis or treatment plan, and no treatment was provided by your facility. EXAMPLE: Patient comes to your institution for a second opinion. Staff physicians order diagnostic tests. The physicians support the original treatment plan. Patient returns to the other institution for treatment.
- Patients who receive transient care to avoid interrupting a course of therapy initiated elsewhere, for example, while vacationing, or because of equipment failure at the original hospital.
- Patients whose medical chart indicates a history of cancer only, and who were diagnosed prior to 1991.
- Patients with in-situ or localized neoplasms of the skin (as listed above).
- Patients with pre-invasive neoplasia of the cervix (as listed above).
TIME FRAME FOR REPORTING
Cases must be reported to the KCR within 6 months from the date of initial diagnosis or date first seen at the reporting facility if not diagnosed there. For those patients seen on an outpatient basis only, the outpatient visit date is considered the date of discharge.
Facilities newly reporting to the KCR for Meaningful Use should report all historical cases entered into the practice electronic medical record system.
ADDITIONAL INFORMATION
For additional information please refer to the KCR website: http://www.kcr.uky.edu/ or contact:
Mr. David Rust, e-mail dave.rust@uky.edu.